Global Capecitabine Market Professional Survey Report 2020
出 版 商：XYZ Research
出版日期：2019/12/01
頁 數：105頁
文件格式：PDF
價 格：
USD 3,500 (Single-User License)
USD 7,000 (Global-User License)
USD 7,000 (Global-User License)
In this report, global Capecitabine Market will reach 1031.47 Million USD by the end of 2022 with a CAGR of -0.17%
The global Capecitabine market is valued at 1040.38 Million USD in 2017 and will reach 1031.47 Million USD by the end of 2022, growing at a CAGR of -0.17% during 2017-2022.
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Capecitabine can be divided into two categories—500 mg type and 150 mg type. 500 mg type production market share accounted for the highest proportion, with a figure of 67.42% in 2017, regenerative type account for 32.58%.
The consumption market share of global Capecitabine in Breast Cancer use, Colorectal cancer use and Stomach Cancer use have been stable year by year, at 40.16%, 31.01% and 28.83% respectively in 2017, and for several consecutive years, the amplitude was within one percent. This indicates that the segment of the Capecitabine in the global market tends to be fixed without great changes. Among them, the Capecitabine market has the most promising sales prospects in Breast Cancer use.
XYZ research center data shows that North America is the biggest contributor to the Capecitabine revenue market, accounted for 54.53% of the total global market with a revenue of 567.37 million USD in 2017, followed by Europe, 28.92% with a revenue of 300.91 million USD.
Roche is the largest company in the global Capecitabine market, accounted for 62.81% of the revenue market share in 2017, followed by Teva and Mylan, accounted for 15.60% and 9.94% of the revenue market share in 2017. These manufacturers range from large multinational corporations to small privately owned companies compete in this industry. The top four producers account for above 90% of the revenue market.
All manufactures in the world are committed to the improvement of product. These two years, some of Chinese and India manufactures can almost catch up with the world's leading technology too. Most technologies are developed by the manufacturers instead of importing from other companies.
This report focuses on top manufacturers in global market, Involved the assessment of Sales, price, revenue and market share for each manufacturer, covering
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Other
...
On the basis of product, this report displays the Sales, revenue, price, market share and growth rate of each type, primarily split into
150mg
500mg
By Application, this report focuses on Sales, Market share and Growth Rate of each application, can be divided into
Breast Cancer
Colorectal Cancer
Stomach Cancer
By Regions, this report splits global market into several key regions, with Sales, Revenue, Price and Gross Margin market share of top players in these regions, from 2014 to 2026 (forecast), like
China
USA
Europe
Japan
Korea
India
Southeast Asia
South America
If you have any special requirements, please let us know and we will offer you the report as you want.
The global Capecitabine market is valued at 1040.38 Million USD in 2017 and will reach 1031.47 Million USD by the end of 2022, growing at a CAGR of -0.17% during 2017-2022.
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Capecitabine can be divided into two categories—500 mg type and 150 mg type. 500 mg type production market share accounted for the highest proportion, with a figure of 67.42% in 2017, regenerative type account for 32.58%.
The consumption market share of global Capecitabine in Breast Cancer use, Colorectal cancer use and Stomach Cancer use have been stable year by year, at 40.16%, 31.01% and 28.83% respectively in 2017, and for several consecutive years, the amplitude was within one percent. This indicates that the segment of the Capecitabine in the global market tends to be fixed without great changes. Among them, the Capecitabine market has the most promising sales prospects in Breast Cancer use.
XYZ research center data shows that North America is the biggest contributor to the Capecitabine revenue market, accounted for 54.53% of the total global market with a revenue of 567.37 million USD in 2017, followed by Europe, 28.92% with a revenue of 300.91 million USD.
Roche is the largest company in the global Capecitabine market, accounted for 62.81% of the revenue market share in 2017, followed by Teva and Mylan, accounted for 15.60% and 9.94% of the revenue market share in 2017. These manufacturers range from large multinational corporations to small privately owned companies compete in this industry. The top four producers account for above 90% of the revenue market.
All manufactures in the world are committed to the improvement of product. These two years, some of Chinese and India manufactures can almost catch up with the world's leading technology too. Most technologies are developed by the manufacturers instead of importing from other companies.
This report focuses on top manufacturers in global market, Involved the assessment of Sales, price, revenue and market share for each manufacturer, covering
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Other
...
On the basis of product, this report displays the Sales, revenue, price, market share and growth rate of each type, primarily split into
150mg
500mg
By Application, this report focuses on Sales, Market share and Growth Rate of each application, can be divided into
Breast Cancer
Colorectal Cancer
Stomach Cancer
By Regions, this report splits global market into several key regions, with Sales, Revenue, Price and Gross Margin market share of top players in these regions, from 2014 to 2026 (forecast), like
China
USA
Europe
Japan
Korea
India
Southeast Asia
South America
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
Global Capecitabine Market Professional Survey Report 2020
1 Report Overview
1.1 Definition and Specification
1.2 Manufacturers and Region Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.3 Type Overview
1.3.1 150mg
1.3.2 500mg
1.4 Application Overview
1.4.1 Breast Cancer
1.4.2 Colorectal Cancer
1.4.3 Stomach Cancer
1.5 Industrial Chain
1.5.1 Capecitabine Industrial Chain
1.5.2 Upstream
1.5.3 Downstream
2.1 The Overall Market Performance(Volume)
2.1.1 150mg
2.1.2 500mg
2.2 The Overall Market Performance(Value)
2.2.1 150mg
2.2.2 500mg
3 Global Capecitabine Market Assessment by Application
3.1 Overall Market Performance (Volume)
3.2 Breast Cancer
3.3 Colorectal Cancer
3.4 Stomach Cancer
4 Competitive Analysis
4.1 Roche
4.1.1 Roche Profiles
4.1.2 Roche Product Information
4.1.3 Roche Capecitabine Business Performance
4.1.4 SWOT Analysis
4.2 Teva
4.2.1 Teva Profiles
4.2.2 Teva Product Information
4.2.3 Teva Capecitabine Business Performance
4.2.4 SWOT Analysis
4.3 Mylan
4.3.1 Mylan Profiles
4.3.2 Mylan Product Information
4.3.3 Mylan Capecitabine Business Performance
4.3.4 SWOT Analysis
4.4 Hikma
4.4.1 Hikma Profiles
4.4.2 Hikma Product Information
4.4.3 Hikma Capecitabine Business Performance
4.4.4 SWOT Analysis
4.5 Hengrui Medicine
4.5.1 Hengrui Medicine Profiles
4.5.2 Hengrui Medicine Product Information
4.5.3 Hengrui Medicine Capecitabine Business Performance
4.5.4 SWOT Analysis
4.6 Cipla
4.6.1 Cipla Profiles
4.6.2 Cipla Product Information
4.6.3 Cipla Capecitabine Business Performance
4.6.4 SWOT Analysis
4.7 Reliance Group
4.7.1 Reliance Group Profiles
4.7.2 Reliance Group Product Information
4.7.3 Reliance Group Capecitabine Business Performance
4.7.4 SWOT Analysis
4.8 Hetero
4.8.1 Hetero Profiles
4.8.2 Hetero Product Information
4.8.3 Hetero Capecitabine Business Performance
4.8.4 SWOT Analysis
4.9 Other
4.9.1 Other Profiles
4.9.2 Other Product Information
4.9.3 Other Capecitabine Business Performance
4.9.4 SWOT Analysis
5 Competitive Lanscape
5.1 Global Capecitabine Capacity (K Units) and Market Share of Manufacturers (2014-2020)
5.2 Global Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
5.3 Global Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
5.4 Global Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
5.5 Global Capecitabine Gross Margin of Manufacturers (2014-2020)
5.6 Market Concentration
6 Regional Market Analysis
6.1 China Market Performance for Manufacturers
6.1.1 China Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.1.2 China Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.1.3 China Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.1.4 China Capecitabine Gross Margin of Manufacturers (2014-2020)
6.1.5 Market Concentration
6.2 USA Market Performance for Manufacturers
6.2.1 USA Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.2.2 USA Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.2.3 USA Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.2.4 USA Capecitabine Gross Margin of Manufacturers (2014-2020)
6.2.5 Market Concentration
6.3 Europe Market Performance for Manufacturers
6.3.1 Europe Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.3.2 Europe Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.3.3 Europe Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.3.4 Europe Capecitabine Gross Margin of Manufacturers (2014-2020)
6.3.5 Market Concentration
6.4 Japan Market Performance for Manufacturers
6.4.1 Japan Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.4.2 Japan Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.4.3 Japan Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.4.4 Japan Capecitabine Gross Margin of Manufacturers (2014-2020)
6.4.5 Market Concentration
6.5 Korea Market Performance for Manufacturers
6.5.1 Korea Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.5.2 Korea Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.5.3 Korea Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.5.4 Korea Capecitabine Gross Margin of Manufacturers (2014-2020)
6.5.5 Market Concentration
6.6 India Market Performance for Manufacturers
6.6.1 India Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.6.2 India Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.6.3 India Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.6.4 India Capecitabine Gross Margin of Manufacturers (2014-2020)
6.6.5 Market Concentration
6.7 Southeast Asia Market Performance for Manufacturers
6.7.1 Southeast Asia Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.7.2 Southeast Asia Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.7.3 Southeast Asia Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.7.4 Southeast Asia Capecitabine Gross Margin of Manufacturers (2014-2020)
6.7.5 Market Concentration
6.8 South America Market Performance for Manufacturers
6.8.1 South America Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.8.2 South America Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.8.3 South America Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.8.4 South America Capecitabine Gross Margin of Manufacturers (2014-2020)
6.8.5 Market Concentration
7 Global Capecitabine Market Assessment by Regions
7.1 Global Capecitabine Capacity (K Units) and Market Share by Regions (2014-2020)
7.2 Global Capecitabine Sales (K Units) and Market Share by Regions (2014-2020)
7.3 Global Capecitabine Revenue (M USD) and Market Share by Regions (2014-2020)
7.4 Global Capecitabine Price (USD/Unit) by Regions (2014-2020)
7.5 Global Capecitabine Gross Margin by Regions (2014-2020)
8 Capacity Analysis of Different Regions
8.1 Global Capecitabine Capacity and Growth Rate (2014-2020)
8.2 China Capecitabine Capacity and Growth Rate (2014-2020)
8.3 USA Capecitabine Capacity and Growth Rate (2014-2020)
8.4 Europe Capecitabine Capacity and Growth Rate (2014-2020)
8.5 Japan Capecitabine Capacity and Growth Rate (2014-2020)
8.6 Korea Capecitabine Capacity and Growth Rate (2014-2020)
8.7 India Capecitabine Capacity and Growth Rate (2014-2020)
8.8 Southeast Asia Capecitabine Capacity and Growth Rate (2014-2020)
8.9 South America Capecitabine Capacity and Growth Rate (2014-2020)
9 Technology and Cost Analysis
9.1 Technology
9.2 Cost
10 Channel Analysis
10.1 Market Channel
10.2 Manufacturing Plants Distribution of Global Capecitabine Major Manufacturers
11 Global Capecitabine Market Forecast by Regions
11.1 Global Capecitabine Market Forecast (2021-2026)
11.1.1 Global Capecitabine Capacity Forecast by Regions (2021-2026)
11.1.2 Global Capecitabine Sales Forecast by Regions (2021-2026)
11.1.2 Global Capecitabine Revenue Forecast by Regions (2021-2026)
11.2 China Capecitabine Market Forecast (2021-2026)
11.3 USA Capecitabine Market Forecast (2021-2026)
11.4 Europe Capecitabine Market Forecast (2021-2026)
11.5 Japan Capecitabine Market Forecast (2021-2026)
11.6 Korea Capecitabine Market Forecast (2021-2026)
11.7 India Capecitabine Market Forecast (2021-2026)
11.8 Southeast Asia Capecitabine Market Forecast (2021-2026)
11.9 South America Capecitabine Market Forecast (2021-2026)
12 Global Capecitabine Market Forecast by Types (2021-2026)
12.1 Overall Market Performance (Sales, Revenue)
12.2 150mg
12.3 500mg
13 Global Capecitabine Market Forecast by Application (2021-2026)
13.1 Overall Market Performance (Sales and Growth Rate)
13.2 Breast Cancer
13.3 Colorectal Cancer
13.4 Stomach Cancer
14 Global Price (USD/Unit) and Gross Profit Forecast
14.1 Global Capecitabine Average Price Forecast (2021-2026)
14.2 Global Capecitabine Gross Profit Forecast (2021-2026)
15 Conclusion
Global Capecitabine Market Professional Survey Report 2020
1 Report Overview
1.1 Definition and Specification
1.2 Manufacturers and Region Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.3 Type Overview
1.3.1 150mg
1.3.2 500mg
1.4 Application Overview
1.4.1 Breast Cancer
1.4.2 Colorectal Cancer
1.4.3 Stomach Cancer
1.5 Industrial Chain
1.5.1 Capecitabine Industrial Chain
1.5.2 Upstream
1.5.3 Downstream
2.1 The Overall Market Performance(Volume)
2.1.1 150mg
2.1.2 500mg
2.2 The Overall Market Performance(Value)
2.2.1 150mg
2.2.2 500mg
3 Global Capecitabine Market Assessment by Application
3.1 Overall Market Performance (Volume)
3.2 Breast Cancer
3.3 Colorectal Cancer
3.4 Stomach Cancer
4 Competitive Analysis
4.1 Roche
4.1.1 Roche Profiles
4.1.2 Roche Product Information
4.1.3 Roche Capecitabine Business Performance
4.1.4 SWOT Analysis
4.2 Teva
4.2.1 Teva Profiles
4.2.2 Teva Product Information
4.2.3 Teva Capecitabine Business Performance
4.2.4 SWOT Analysis
4.3 Mylan
4.3.1 Mylan Profiles
4.3.2 Mylan Product Information
4.3.3 Mylan Capecitabine Business Performance
4.3.4 SWOT Analysis
4.4 Hikma
4.4.1 Hikma Profiles
4.4.2 Hikma Product Information
4.4.3 Hikma Capecitabine Business Performance
4.4.4 SWOT Analysis
4.5 Hengrui Medicine
4.5.1 Hengrui Medicine Profiles
4.5.2 Hengrui Medicine Product Information
4.5.3 Hengrui Medicine Capecitabine Business Performance
4.5.4 SWOT Analysis
4.6 Cipla
4.6.1 Cipla Profiles
4.6.2 Cipla Product Information
4.6.3 Cipla Capecitabine Business Performance
4.6.4 SWOT Analysis
4.7 Reliance Group
4.7.1 Reliance Group Profiles
4.7.2 Reliance Group Product Information
4.7.3 Reliance Group Capecitabine Business Performance
4.7.4 SWOT Analysis
4.8 Hetero
4.8.1 Hetero Profiles
4.8.2 Hetero Product Information
4.8.3 Hetero Capecitabine Business Performance
4.8.4 SWOT Analysis
4.9 Other
4.9.1 Other Profiles
4.9.2 Other Product Information
4.9.3 Other Capecitabine Business Performance
4.9.4 SWOT Analysis
5 Competitive Lanscape
5.1 Global Capecitabine Capacity (K Units) and Market Share of Manufacturers (2014-2020)
5.2 Global Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
5.3 Global Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
5.4 Global Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
5.5 Global Capecitabine Gross Margin of Manufacturers (2014-2020)
5.6 Market Concentration
6 Regional Market Analysis
6.1 China Market Performance for Manufacturers
6.1.1 China Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.1.2 China Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.1.3 China Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.1.4 China Capecitabine Gross Margin of Manufacturers (2014-2020)
6.1.5 Market Concentration
6.2 USA Market Performance for Manufacturers
6.2.1 USA Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.2.2 USA Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.2.3 USA Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.2.4 USA Capecitabine Gross Margin of Manufacturers (2014-2020)
6.2.5 Market Concentration
6.3 Europe Market Performance for Manufacturers
6.3.1 Europe Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.3.2 Europe Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.3.3 Europe Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.3.4 Europe Capecitabine Gross Margin of Manufacturers (2014-2020)
6.3.5 Market Concentration
6.4 Japan Market Performance for Manufacturers
6.4.1 Japan Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.4.2 Japan Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.4.3 Japan Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.4.4 Japan Capecitabine Gross Margin of Manufacturers (2014-2020)
6.4.5 Market Concentration
6.5 Korea Market Performance for Manufacturers
6.5.1 Korea Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.5.2 Korea Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.5.3 Korea Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.5.4 Korea Capecitabine Gross Margin of Manufacturers (2014-2020)
6.5.5 Market Concentration
6.6 India Market Performance for Manufacturers
6.6.1 India Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.6.2 India Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.6.3 India Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.6.4 India Capecitabine Gross Margin of Manufacturers (2014-2020)
6.6.5 Market Concentration
6.7 Southeast Asia Market Performance for Manufacturers
6.7.1 Southeast Asia Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.7.2 Southeast Asia Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.7.3 Southeast Asia Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.7.4 Southeast Asia Capecitabine Gross Margin of Manufacturers (2014-2020)
6.7.5 Market Concentration
6.8 South America Market Performance for Manufacturers
6.8.1 South America Capecitabine Sales (K Units) and Market Share of Manufacturers (2014-2020)
6.8.2 South America Capecitabine Revenue (M USD) and Market Share of Manufacturers (2014-2020)
6.8.3 South America Capecitabine Price (USD/Unit) of Manufacturers (2014-2020)
6.8.4 South America Capecitabine Gross Margin of Manufacturers (2014-2020)
6.8.5 Market Concentration
7 Global Capecitabine Market Assessment by Regions
7.1 Global Capecitabine Capacity (K Units) and Market Share by Regions (2014-2020)
7.2 Global Capecitabine Sales (K Units) and Market Share by Regions (2014-2020)
7.3 Global Capecitabine Revenue (M USD) and Market Share by Regions (2014-2020)
7.4 Global Capecitabine Price (USD/Unit) by Regions (2014-2020)
7.5 Global Capecitabine Gross Margin by Regions (2014-2020)
8 Capacity Analysis of Different Regions
8.1 Global Capecitabine Capacity and Growth Rate (2014-2020)
8.2 China Capecitabine Capacity and Growth Rate (2014-2020)
8.3 USA Capecitabine Capacity and Growth Rate (2014-2020)
8.4 Europe Capecitabine Capacity and Growth Rate (2014-2020)
8.5 Japan Capecitabine Capacity and Growth Rate (2014-2020)
8.6 Korea Capecitabine Capacity and Growth Rate (2014-2020)
8.7 India Capecitabine Capacity and Growth Rate (2014-2020)
8.8 Southeast Asia Capecitabine Capacity and Growth Rate (2014-2020)
8.9 South America Capecitabine Capacity and Growth Rate (2014-2020)
9 Technology and Cost Analysis
9.1 Technology
9.2 Cost
10 Channel Analysis
10.1 Market Channel
10.2 Manufacturing Plants Distribution of Global Capecitabine Major Manufacturers
11 Global Capecitabine Market Forecast by Regions
11.1 Global Capecitabine Market Forecast (2021-2026)
11.1.1 Global Capecitabine Capacity Forecast by Regions (2021-2026)
11.1.2 Global Capecitabine Sales Forecast by Regions (2021-2026)
11.1.2 Global Capecitabine Revenue Forecast by Regions (2021-2026)
11.2 China Capecitabine Market Forecast (2021-2026)
11.3 USA Capecitabine Market Forecast (2021-2026)
11.4 Europe Capecitabine Market Forecast (2021-2026)
11.5 Japan Capecitabine Market Forecast (2021-2026)
11.6 Korea Capecitabine Market Forecast (2021-2026)
11.7 India Capecitabine Market Forecast (2021-2026)
11.8 Southeast Asia Capecitabine Market Forecast (2021-2026)
11.9 South America Capecitabine Market Forecast (2021-2026)
12 Global Capecitabine Market Forecast by Types (2021-2026)
12.1 Overall Market Performance (Sales, Revenue)
12.2 150mg
12.3 500mg
13 Global Capecitabine Market Forecast by Application (2021-2026)
13.1 Overall Market Performance (Sales and Growth Rate)
13.2 Breast Cancer
13.3 Colorectal Cancer
13.4 Stomach Cancer
14 Global Price (USD/Unit) and Gross Profit Forecast
14.1 Global Capecitabine Average Price Forecast (2021-2026)
14.2 Global Capecitabine Gross Profit Forecast (2021-2026)
15 Conclusion
